{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:00:05Z","timestamp":1762866005602},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T00:00:00Z","timestamp":1343779200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Comput Aided Mol Des"],"published-print":{"date-parts":[[2012,8]]},"DOI":"10.1007\/s10822-012-9593-7","type":"journal-article","created":{"date-parts":[[2012,8,10]],"date-time":"2012-08-10T11:49:49Z","timestamp":1344599389000},"page":"983-992","source":"Crossref","is-referenced-by-count":7,"title":["Identification of common inhibitors of wild-type and T315I mutant of BCR-ABL through the parallel structure-based virtual screening"],"prefix":"10.1007","volume":"26","author":[{"given":"Hwangseo","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seunghee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungwoo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,8,11]]},"reference":[{"key":"9593_CR1","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","volume":"113","author":"A Quintas-Cardama","year":"2009","unstructured":"Quintas-Cardama A, Cortes J (2009) Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:1619\u20131630","journal-title":"Blood"},{"key":"9593_CR2","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ceb.2009.01.014","volume":"21","author":"MJ Eck","year":"2009","unstructured":"Eck MJ, Manley PW (2009) The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Curr Opin Cell Biol 21:288\u2013295","journal-title":"Curr Opin Cell Biol"},{"key":"9593_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.20175","volume":"31","author":"S Schenone","year":"2010","unstructured":"Schenone S, Bruno O, Radi M, Botta M (2010) New insights into small-molecule inhibitors of Bcr-Abl. Med Res Rev 31:1\u201341","journal-title":"Med Res Rev"},{"key":"9593_CR4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","volume":"1","author":"R Capdeville","year":"2002","unstructured":"Capdeville R, Buchdunger E, Zimmermann J, Matter A (2002) Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1:493\u2013503","journal-title":"Nat Rev Drug Discov"},{"key":"9593_CR5","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2019Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110:2242\u20132249","journal-title":"Blood"},{"key":"9593_CR6","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nrd2324","volume":"6","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama A, Kantarjian H, Cortes J (2007) Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 6:834\u2013848","journal-title":"Nat Rev Drug Discov"},{"key":"9593_CR7","doi-asserted-by":"crossref","first-page":"6658","DOI":"10.1021\/jm049486a","volume":"47","author":"LJ Lombardo","year":"2004","unstructured":"Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LAM, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM (2004) Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src\/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 47:6658\u20136661","journal-title":"J Med Chem"},{"key":"9593_CR8","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","volume":"7","author":"E Weisberg","year":"2005","unstructured":"Weisberg E, Manley PW, Breitenstein W, Br\u00fcggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Azam M, Neuberg D, Wright RD, Gilliland DG, Griffin JD (2005) Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 7:129\u2013141","journal-title":"Cancer Cell"},{"key":"9593_CR9","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.1182\/blood-2005-06-2209","volume":"106","author":"S Kimura","year":"2005","unstructured":"Kimura S, Naito H, Segawa H, Kuroda J, Yuasa T, Sato K, Yokota A, Kamitsuji Y, Kawata E, Ashihara E, Nakaya Y, Naruoka H, Wakayama T, Nasu K, Asaki T, Niwa T, Hirabayashi K, Maekawa T (2005) NS-187, a potent and selective dual Bcr-Abl\/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 106:3948\u20133954","journal-title":"Blood"},{"key":"9593_CR10","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1021\/jm0102250","volume":"44","author":"DH Boschelli","year":"2001","unstructured":"Boschelli DH, Ye F, Wang YD, Dutia M, Johnson SL, Wu B, Miller K, Powell DW, Yaczko D, Young M, Tischler M, Arndt K, Discafani C, Etienne C, Gibbons J, Grod J, Lucas J, Weber JM, Boschelli F (2001) Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity. J Med Chem 44:3965\u20133977","journal-title":"J Med Chem"},{"key":"9593_CR11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1747-0285.2007.00556.x","volume":"70","author":"T Zhou","year":"2007","unstructured":"Zhou T, Parillon L, Li F, Wang Y, Keats J, Lamore S, Xu Q, Shakespeare W, Dalgarno D, Zhu X (2007) Crystal structure of the T315I mutant of Abl kinase. Chem Biol Drug Des 70:171\u2013181","journal-title":"Chem Biol Drug Des"},{"key":"9593_CR12","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","volume":"109","author":"FJ Giles","year":"2007","unstructured":"Giles FJ, Cortes J, Jones D, Bergstrom D, Kantarjian H, Freedman SJ (2007) MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 109:500\u2013502","journal-title":"Blood"},{"key":"9593_CR13","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","volume":"111","author":"A Gontarewicz","year":"2008","unstructured":"Gontarewicz A, Balabanov S, Keller G, Colombo R, Graziano A, Pesenti E, Benten D, Bokemeyer C, Fiedler W, Moll J, Br\u00fcmmendorf TH (2008) Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 111:4355\u20134364","journal-title":"Blood"},{"key":"9593_CR14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1021\/jm800984v","volume":"52","author":"S Howard","year":"2009","unstructured":"Howard S, Berdini V, Boulstridge JA, Carr MG, Cross DM, Curry J, Devine LA, Early TR, Fazal L, Gill AL, Heathcote M, Maman S, Matthews JE, McMenamin RL, Navarro EF, O\u2019Brien MA, O\u2019Reilly M, Rees DC, Reule M, Tisi D, Williams G, Vinkovi\u0107 M, Wyatt PG (2009) Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem 52:379\u2013388","journal-title":"J Med Chem"},{"key":"9593_CR15","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1182\/blood-2009-01-199307","volume":"114","author":"Y Shiotsu","year":"2009","unstructured":"Shiotsu Y, Kiyoi H, Ishikawa Y, Tanizaki R, Shimizu M, Umehara H, Ishii K, Mori Y, Ozeki K, Minami Y, Abe A, Maeda H, Akiyama T, Kanda Y, Sato Y, Akinaga S, Naoe T (2009) KW-2449, a novel multikinase inhibitor, suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR\/ABL translocation. Blood 114:1607\u20131617","journal-title":"Blood"},{"key":"9593_CR16","doi-asserted-by":"crossref","first-page":"4392","DOI":"10.1158\/1078-0432.CCR-08-0117","volume":"14","author":"A Quintas-Cardama","year":"2008","unstructured":"Quintas-Cardama A, Cortes J (2008) Therapeutic options against BCR-ABL1 T315I positive chronic myelogenous leukemia. Clin Cancer Res 14:4392\u20134399","journal-title":"Clin Cancer Res"},{"key":"9593_CR17","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1021\/jm901808w","volume":"53","author":"HG Choi","year":"2010","unstructured":"Choi HG, Ren P, Adrian F, Sun F, Lee HS, Wang X, Ding Q, Zhang G, Xie Y, Zhang J, Liu Y, Tuntland T, Warmuth M, Manley PW, Mestan J, Gray NS, Sim T (2010) A type-II kinase inhibitor capable of inhibiting the T315I \u201cgatekeeper\u201d mutant of Bcr-Abl. J Med Chem 53:5439\u20135448","journal-title":"J Med Chem"},{"key":"9593_CR18","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"WS Huang","year":"2010","unstructured":"Huang WS, Metcalf CA, Sundaramoorthi R, Wang Y, Zou D, Thomas RM, Zhu X, Cai L, Wen D, Liu S, Romero J, Qi J, Chen I, Banda G, Lentini SP, Das S, Xu Q, Keats J, Wang F, Wardwell S, Ning Y, Snodgrass JT, Broudy MI, Russian K, Zhou T, Commodore L, Narasimhan NI, Mohemmad QK, Iuliucci J, Rivera VM, Dalgarno DC, Sawyer TK, Clackson T, Shakespeare WC (2010) Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 53:4701\u20134719","journal-title":"J Med Chem"},{"key":"9593_CR19","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.1016\/j.bmcl.2011.04.060","volume":"21","author":"M Thomas","year":"2011","unstructured":"Thomas M, Huang WS, Wen D, Zhu X, Wang Y, Metcalf CA, Liu S, Chen I, Romero J, Zou D, Sundaramoorthi R, Li F, Qi J, Cai L, Zhou T, Commodore L, Xu Q, Keats J, Wang F, Wardwell S, Ning Y, Snodgrass JT, Broudy MI, Russian K, Iuliucci J, Rivera VM, Sawyer TK, Dalgarno DC, Clackson T, Shakespeare WC (2011) Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR\u2013ABL including the T315I gatekeeper mutant. Bioorg Med Chem Lett 21:3743\u20133748","journal-title":"Bioorg Med Chem Lett"},{"key":"9593_CR20","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1016\/j.bmcl.2010.05.043","volume":"20","author":"X Deng","year":"2010","unstructured":"Deng X, Lim SM, Zhang J, Gray NS (2010) Broad spectrum alkynyl inhibitors of T315I Bcr-Abl. Bioorg Med Chem Lett 20:4196\u20134200","journal-title":"Bioorg Med Chem Lett"},{"key":"9593_CR21","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1016\/j.bmcl.2007.08.043","volume":"17","author":"J Cao","year":"2007","unstructured":"Cao J, Fine R, Gritzen C, Hood J, Kang X, Klebansky B, Lohse D, Mak CC, McPherson A, Noronha G, Palanki MSS, Pathak VP, Renick J, Soll R, Zeng B, Zhu H (2007) The design and preliminary structure\u2013activity relationship studies of benzotriazines as potent inhibitors of Abl and Abl-T315I enzymes. Bioorg Med Chem Lett 17:5812\u20135818","journal-title":"Bioorg Med Chem Lett"},{"key":"9593_CR22","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1038\/sj.leu.2403775","volume":"19","author":"C Gambacorti-Passerini","year":"2005","unstructured":"Gambacorti-Passerini C, Gasser M, Ahmed S, Assouline S, Scapozza L (2005) Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies. Leukemia 19:1267\u20131269","journal-title":"Leukemia"},{"key":"9593_CR23","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1016\/j.bmcl.2011.09.127","volume":"21","author":"S L\u00fc","year":"2011","unstructured":"L\u00fc S, Luo Q, Hao X, Li X, Ji L, Zheng W, Wang F (2011) Synthesis and docking study of 2-phenylaminopyrimidine Abl tyrosine kinase inhibitors. Bioorg Med Chem Lett 21:6964\u20136968","journal-title":"Bioorg Med Chem Lett"},{"key":"9593_CR24","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.bmcl.2011.02.029","volume":"21","author":"D Wang","year":"2011","unstructured":"Wang D, Zhang Z, Lu X, Feng Y, Luo K, Gan J, Yingxue L, Wan J, Li X, Zhang F, Tu Z, Cai Q, Ren X, Ding K (2011) Hybrid compounds as new Bcr\/Abl inhibitors. Bioorg Med Chem Lett 21:1965\u20131968","journal-title":"Bioorg Med Chem Lett"},{"key":"9593_CR25","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1021\/jm050362n","volume":"49","author":"GL Warren","year":"2006","unstructured":"Warren GL, Andrews CW, Capelli AM, Clarke B, LaLonde J, Lambert MH, Lindvall M, Nevins N, Semus SF, Senger S, Tedesco G, Wall ID, Woolven JM, Peishoff CE, Head MS (2006) A critical assessment of docking programs and scoring functions. J Med Chem 49:5912\u20135931","journal-title":"J Med Chem"},{"key":"9593_CR26","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/(SICI)1097-0134(19990101)34:1<4::AID-PROT2>3.0.CO;2-6","volume":"34","author":"BK Shoichet","year":"1999","unstructured":"Shoichet BK, Leach AR, Kuntz ID (1999) Ligand solvation in molecular docking. Proteins 34:4\u201316","journal-title":"Proteins"},{"key":"9593_CR27","first-page":"4236","volume":"62","author":"B Nagar","year":"2002","unstructured":"Nagar B, Bornmann W, Pellicena P, Schindler T, Veach DR, Miller WT, Clarkson B, Kuriyan J (2002) Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 62:4236\u20134243","journal-title":"Cancer Res"},{"key":"9593_CR28","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401\u2013412","journal-title":"Cancer Cell"},{"key":"9593_CR29","volume-title":"An introduction to hydrogen bonding","author":"GA Jeffrey","year":"1997","unstructured":"Jeffrey GA (1997) An introduction to hydrogen bonding. Oxford University Press, Oxford"},{"key":"9593_CR30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(96)00423-1","volume":"23","author":"CA Lipinski","year":"1997","unstructured":"Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (1997) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliver Rev 23:3\u201325","journal-title":"Adv Drug Deliver Rev"},{"key":"9593_CR31","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1016\/0040-4020(80)80168-2","volume":"36","author":"J Gasteiger","year":"1980","unstructured":"Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity\u2014a rapid access to atomic charges. Tetrahedron 36:3219\u20133228","journal-title":"Tetrahedron"},{"key":"9593_CR32","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","volume":"19","author":"GM Morris","year":"1998","unstructured":"Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639\u20131662","journal-title":"J Comput Chem"},{"key":"9593_CR33","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/prot.21183","volume":"65","author":"H Park","year":"2006","unstructured":"Park H, Lee J, Lee S (2006) Critical assessment of the automated AutoDock as a new docking tool for virtual screening. Proteins 65:549\u2013554","journal-title":"Proteins"},{"key":"9593_CR34","doi-asserted-by":"crossref","first-page":"021916","DOI":"10.1103\/PhysRevE.75.021916","volume":"75","author":"H Park","year":"2007","unstructured":"Park H, Jeon YH (2007) Cubic equation governing the outer-region dielectric constant of globular proteins. Phys Rev E 75:021916","journal-title":"Phys Rev E"},{"key":"9593_CR35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/08927029308022161","volume":"10","author":"PFW Stouten","year":"1993","unstructured":"Stouten PFW, Fr\u00f6mmel C, Nakamura H, Sander C (1993) An effective solvation term based on atomic occupancies for use in protein simulations. Mol Simul 10:97\u2013120","journal-title":"Mol Simul"},{"key":"9593_CR36","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1021\/ci600453b","volume":"47","author":"H Kang","year":"2007","unstructured":"Kang H, Choi H, Park H (2007) Prediction of molecular solvation free energy based on the optimization of atomic solvation parameters with genetic algorithm. J Chem Inf Model 47:509\u2013514","journal-title":"J Chem Inf Model"},{"key":"9593_CR37","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s10822-011-9432-2","volume":"25","author":"H Park","year":"2011","unstructured":"Park H, Jeon JY, Kim SY, Jeong DG, Ryu SE (2011) Identification of novel inhibitors of mitogen-activated protein kinase phosphatase-1 with structure-based virtual screening. J Comput Aided Mol Des 25:469\u2013475","journal-title":"J Comput Aided Mol Des"},{"key":"9593_CR38","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1021\/ci200378s","volume":"51","author":"H Park","year":"2011","unstructured":"Park H, Chi O, Kim J, Hong S (2011) Identification of novel inhibitors of tropomyosin-related kinase A through the structure-based virtual screening with homology-modeled protein structure. J Chem Inf Model 51:2986\u20132993","journal-title":"J Chem Inf Model"},{"key":"9593_CR39","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","volume":"23","author":"MA Fabian","year":"2005","unstructured":"Fabian MA, Biggs WH III, Treiber DK, Atteridge CE, Azimioara MD, Bendetti MG, Carter TA, Ciceri P, Edeen PT, Floyd M, Ford JM, Galvin M, Gerlach JL, Grotzfeld RM, Herrgard S, Insko DE, Insko MA, Lai AG, Lelias JM, Mehta SA, Milanov ZV, Velasco AM, Wodicka LM, Patel HK, Zarrinkar PP, Lockhart DJ (2005) A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol 23:329\u2013336","journal-title":"Nat Biotechnol"},{"key":"9593_CR40","doi-asserted-by":"crossref","unstructured":"Hassan AQ, Sharma SV, Warmuth M (2010) Allosteric inhibition of BCR-ABL. Cell Cycle 9:3710\u20133714","DOI":"10.4161\/cc.9.18.13232"}],"container-title":["Journal of Computer-Aided Molecular Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-012-9593-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10822-012-9593-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10822-012-9593-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T01:23:10Z","timestamp":1559265790000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10822-012-9593-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,8]]}},"alternative-id":["9593"],"URL":"https:\/\/doi.org\/10.1007\/s10822-012-9593-7","relation":{},"ISSN":["0920-654X","1573-4951"],"issn-type":[{"value":"0920-654X","type":"print"},{"value":"1573-4951","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,8]]}}}